Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience

• Published in: Acta diabetologica 2014-10, Vol.51 (5), p.833-843
• Main Authors: Qi, Meirigeng, Kinzer, Katie, Danielson, Kirstie K., Martellotto, Joan, Barbaro, Barbara, Wang, Yong, Bui, James T., Gaba, Ron C., Knuttinen, Grace, Garcia-Roca, Raquel, Tzvetanov, Ivo, Heitman, Andrew, Davis, Maureen, McGarrigle, James J., Benedetti, Enrico, Oberholzer, Jose
• Format: Article
• Language: English
• Subjects: Adult; Aged; Blood Glucose - metabolism; C-Peptide - blood; Chicago; Clinical outcomes; Diabetes; Diabetes Mellitus, Type 1 - metabolism; Diabetes Mellitus, Type 1 - surgery; Female; Follow-Up Studies; Glycated Hemoglobin A - metabolism; Hospitals, University; Humans; Insulin; Insulin - blood; Internal Medicine; Islets of Langerhans Transplantation; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Original Article; Prospective Studies; Transplantation, Homologous; Transplants & implants
• ISSN: 0940-5429; 1432-5233
• DOI: 10.1007/s00592-014-0627-6

This report summarizes a 5-year phase 1/2 allogeneic islet transplantation clinical trial conducted at the University of Illinois at Chicago (UIC). Ten patients were enrolled in this single center, open label, and prospective trial in which patients received 1–3 transplants. The first four subjects underwent islet transplantation with the Edmonton immunosuppressive regimen and the remaining six subjects received the UIC immunosuppressive protocol (Edmonton plus etanercept and exenatide). All 10 patients achieved insulin independence after 1–3 transplants. At 5 years of follow-up, 6 of the initial 10 patients were free of exogenous insulin. During the follow-up period, 7 of the 10 patients maintained positive C-peptide levels and a composite hypoglycemic score of 0. Most patients maintained HbA1c levels